Gemlapodect (NOE-105) is an investigational phosphodiesterase-10A inhibitor being evaluated for the treatment of tic disorders, including Tourette syndrome. A Phase 2a study indicated that gemlapodect successfully reduced tic severity without significant safety concerns, reporting only mild adverse events. Subsequent Phase 2b trials have been initiated to further test its efficacy and safety across a more diverse population of individuals with Tourette syndrome.

Appalachian State University

Google

Individualized care is the most important treatment plan for patients with tic disorders. Other methods used include Cognitive Behavioral Intervention for Tics (CBIT), medications, and interventions. Medications used are alpha-2 agonists and antipsychotics. Interventions may include Botox or deep-brain stimulation (DBS) techniques.

Treatments rarely eliminate all tics, but work to lessen their severity.

Treatment for Tic Disorders

Gilbert, D. L., Murphy, T. K., Jankovic, J., Budman, C. L., Black, K. J., Kurlan, R. M., Coffman, K. A., McCracken, J. T., Juncos, J., Grant, J. E., & Chipkin, R. E. (2018). Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Movement disorders : official journal of the Movement Disorder Society, 33(8), 1272–1280. https://doi.org/10.1002/mds.27457 

References for New Drug Treatments for Tic Disorders

Findings associated with the drug, Ecopipam, found that it decreased the severity of tics. This drug is a dopamine blocker, specifically, it blocks dopamine-1 receptors. Studies have found that, compared to a placebo, both motor and vocal tic measures were reduced. Another key finding was the lack of side effects, metabolic or antipsychotic, as is seen in other medications. However, studies are continuing with larger sample sizes to reinforce the potential role of the drug in treating tic disorders.

Learn Before

Related